Transforming growth factor beta (TGFB) is a pleiotropic cytokine, known to be dysregulated in many neurodegenerative disorders and particularly in amyotrophic lateral sclerosis (ALS). This motor neuronal disease is non-cell autonomous, as it affects not only motor neurons, but also their surrounding glial cells, and their target skeletal muscle fibers. Here, we analyze the multiple roles of TGFB in these cell types, and how TGFB signaling is altered in ALS tissues. Data reported support a crucial involvement of TGFB in the etiology and progression of ALS, leading us to hypothesize that an imbalance of TGFB signaling, diminished at the pre-symptomatic stage and then increased with time, could be linked to ALS progression. A reduced stimulation of the TGFB pathway at the beginning of disease blocks its neuroprotective effects and promotes glutamate excitotoxicity. At later disease stages, the persistent activation of the TGFB pathway promotes an excessive microglial activation and strengthens muscular dysfunction. The therapeutic potential of TGFB is discussed here, in order to foster new approaches to treat ALS.

Multiple Roles of Transforming Growth Factor Beta in Amyotrophic Lateral Sclerosis / M. Galbiati, V. Crippa, P. Rusmini, R.M. Cristofani, E. Messi, M. Piccolella, B. Tedesco, V. Ferrari, E. Casarotto, M. Chierichetti, A. Poletti. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 21:12(2020 Jun 16). [10.3390/ijms21124291]

Multiple Roles of Transforming Growth Factor Beta in Amyotrophic Lateral Sclerosis

M. Galbiati
Primo
;
V. Crippa
Secondo
;
P. Rusmini;R.M. Cristofani;E. Messi;M. Piccolella;B. Tedesco;V. Ferrari;E. Casarotto;M. Chierichetti
Penultimo
;
A. Poletti
Ultimo
2020

Abstract

Transforming growth factor beta (TGFB) is a pleiotropic cytokine, known to be dysregulated in many neurodegenerative disorders and particularly in amyotrophic lateral sclerosis (ALS). This motor neuronal disease is non-cell autonomous, as it affects not only motor neurons, but also their surrounding glial cells, and their target skeletal muscle fibers. Here, we analyze the multiple roles of TGFB in these cell types, and how TGFB signaling is altered in ALS tissues. Data reported support a crucial involvement of TGFB in the etiology and progression of ALS, leading us to hypothesize that an imbalance of TGFB signaling, diminished at the pre-symptomatic stage and then increased with time, could be linked to ALS progression. A reduced stimulation of the TGFB pathway at the beginning of disease blocks its neuroprotective effects and promotes glutamate excitotoxicity. At later disease stages, the persistent activation of the TGFB pathway promotes an excessive microglial activation and strengthens muscular dysfunction. The therapeutic potential of TGFB is discussed here, in order to foster new approaches to treat ALS.
ALS; TGFB; motor neuron; glial cells; skeletal muscle ; SMAD
Settore BIO/09 - Fisiologia
Settore BIO/13 - Biologia Applicata
   From RNA to Protein toxicity in motorneuron diseases
   MINISTERO DELL'ISTRUZIONE E DEL MERITO
   2015LFPNMN_001

   Translating molecular mechanisms into ALS risk and patient's well-being
   TRANS-ALS
   FONDAZIONE REGIONALE PER LA RICERCA BIOMEDICA
   2015-0023

   RAN translation of normal and expanded nucleotide repeat containing transcripts to neurotoxic polypetides in neurodegenerative diseases
   No RAn for old man
   FONDAZIONE CARIPLO
   2014-0686

   Alternative translation initiation as a novel strategy to block toxicity of the mutant Androgen Receptor in SBMA
   FONDAZIONE TELETHON ETS
   GGP19128

   Selective translation of androgen receptor isoform A to prevent polyQ mediated toxicity in Kennedy’s disease
   KENNEDY'S DISEASE ASSOCIATION

   Extracellular vescicles in the pathogenesis of frontotemporal dementia
   FONDAZIONE CARIPLO
   2017-0747

   Stress granules and proteostasis in motor neurons: towards a mechanistic understanding of ALS (CureALS)
   CureALS
   MINISTERO DELL'ISTRUZIONE E DEL MERITO

   Membrane-less organelle pathology in ALS: identification of causes and rescuing factors (MLOMALS)
   MLOMALS
   FONDAZIONE ITALIANA DI RICERCA PER LA SLA - SCLEROSI LATERALE AMIOTROFICA - ARISLA

   Colchicine for Amyotrophic Lateral Sclerosis: a phase II, randomized, double blind, placebo controlled, multicenter clinical trial (Co-ALS)
   Co-ALS
   AGENZIA ITALIANA DEL FARMACO - AIFA
   AIFA-2016-02364678

   Targeting RAN translation in ALS (Target-RAN)
   Target-RAN
   FONDAZIONE ITALIANA DI RICERCA PER LA SLA - SCLEROSI LATERALE AMIOTROFICA - ARISLA

   The interplay between the “rna/protein quality control system” and “exosomes” as a spreading mechanism in amyotrophic lateral sclerosis (EX_ALS)
   EX_ALS
   MINISTERO DELL'ISTRUZIONE E DEL MERITO
   2017F2A2C5_001

   Extracellular vescicles in the pathogenesis of frontotemporal dementia
   FONDAZIONE CARIPLO
   2017-0747

   Motor neuron degeneration in Spinal and Bulbar Muscular Atrophy: molecular approaches to counteract mutant androgen receptor neurotoxicity
   FONDAZIONE TELETHON ETS
   GGP14039

   Ruolo protettivo della proteina HSPB8 nelle malattie del motoneurone
   MINISTERO DELLA SALUTE
   02347198

   Upregulation of HSPB8 as potential therapeutic approach in familial and sporadic ALS
   ALS_HSPB8
   FONDAZIONE ITALIANA DI RICERCA PER LA SLA - SCLEROSI LATERALE AMIOTROFICA - ARISLA
   ALS_HSPB8
16-giu-2020
Centro Interdipartimentale di Eccellenza per le Malattie Neurodegenerative CEND
Article (author)
File in questo prodotto:
File Dimensione Formato  
final.pdf

accesso aperto

Descrizione: Articolo principale versione accettata dall'editore
Tipologia: Publisher's version/PDF
Dimensione 713.38 kB
Formato Adobe PDF
713.38 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/741344
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 26
social impact